Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.26%AUDUSD-1.13%GBPCHF+0.99%AUDJPY-0.89%USDCHF+0.83%GBPCAD+0.79%USDCAD+0.66%EURGBP-0.66%GBPNZD+0.65%EURAUD+0.62%AUDNZD-0.60%USDTHB+0.58%CHFJPY-0.54%NZDUSD-0.53%EURUSD-0.53%AUDCAD-0.50%GBPTRY+0.41%GBPJPY+0.40%CADJPY-0.39%GBPHKD+0.32%AUDCHF-0.32%NZDCHF+0.31%EURCHF+0.30%USDTRY+0.29%GBPMXN-0.28%EURJPY-0.27%USDJPY+0.25%NZDJPY-0.25%USDCNH-0.19%CADCHF+0.18%SGDJPY+0.17%PLNJPY+0.17%USDILS+0.16%NOKJPY+0.14%GBPUSD+0.14%EURCAD+0.13%NZDCAD+0.13%EURZAR+0.10%USDZAR+0.09%GBPZAR+0.09%CHFNOK+0.08%EURNOK+0.05%USDCOP-0.04%EURCZK-0.04%CHFSEK+0.04%CHFSGD+0.04%USDHKD+0.04%AUDNOK+0.04%USDMXN+0.03%USDNOK+0.03%EURPLN+0.02%NZDMXN+0.02%USDDKK-0.02%AUDDKK-0.02%EURNZD+0.02%EURCNH+0.02%USDSEK-0.01%EURSGD+0.01%USDPLN+0.01%EURSEK+0.01%GBPSGD0.00%EURHKD0.00%EURDKK0.00%USDSGD0.00%AUDSGD0.00%NZDSGD0.00%XPTUSD-0.88%GAGUSD-0.55%XAGUSD-0.55%HG1-0.37%W1+0.31%GAUUSD-0.28%XAUUSD-0.28%XNGUSD+0.21%UKOIL+0.16%S1-0.13%C1+0.13%USOIL+0.02%BTCUSD-0.23%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.10%ZECUSDT+0.54%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.54%XLMUSD+1.65%BCHUSDT-0.58%UNIUSD-0.31%LTCUSD+0.07%HBARUSDT+2.14%SUIUSD+0.84%TONUSD+15.77%TAOUSDT+0.14%AAVEUSD-3.72%DOTUSDT+2.53%ICPUSDT-3.35%ONDOUSDT-0.32%WLDUSDT+10.71%ARBUSDT-0.49%JUPUSDT-0.20%ATOMUSDT+1.04%INJUSDT-2.78%STXUSDT+17.38%FETUSDT+1.99%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.04%OPUSDT+0.54%WIFUSDT+3.46%IOTAUSDT+4.43%POLUSDT-4.36%AXSUSDT+0.76%FARTCOINUSDT-0.45%EOSUSDT+4.55%DYDXUSDT+3.32%GALAUSDT+4.30%ORDIUSDT+1.19%NOTUSDT+1.55%RONINUSDT+0.85%
BP

BridgeBio Pharma, Inc. (BBIO)

NASDAQ • Healthcare

$65.8
-$0.17 (-0.3%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$66.14
Day Range$65.74 - $67.29
Avg. Volume (3M)2.8M
Market Cap$12.8B
52 Week Range
$51.85$93.42
Next EarningsIn 27 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$222.4M100%
Gross Profitminus cost of goods$207.3M93%

In plain terms: out of every $100 in revenue, BridgeBio Pharma, Inc. currently loses $68.

Fundamentals & Financials

Revenue (TTM)
$691.8M
Net Income (TTM)
-$696.2M
EPS (TTM)
-$3.58
ROA (TTM)
-57.2%
Current Ratio
1.23
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-40.2%Q1 2026-$1
-23.8%Q2 2026-$0.84
-35.5%Q3 2026-$0.78
Next

Oct 28

in 27 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -35.5%

BridgeBio Pharma’s earnings missed on EPS even as revenue more than doubled year over year in the second fiscal quarter of 2026, which it reported on August 10, 2026. Revenue rose 101.2% to about $222.4 million (up from about $110.6 million a year ago), while EPS of -$0.78 trailed the -$0.58 estimate by -$0.20 and improved 17.9% from -$0.95 a year earlier. Profitability stayed characterized by a high gross margin of ~93% alongside a -48.1% operating margin, with gross profit of roughly $207.4 million and operating income of about -$107.1 million. Net income was about -$152.2 million, narrowing 16.3% versus about -$181.9 million in the prior-year quarter. Cash flow from operations was negative at roughly -$223.3 million, and the company repurchased about $127.5 million of stock during the quarter. Consensus for the next period calls for EPS of -$0.67.

Next report — what to expect

BridgeBio Pharma, Inc. (BBIO) is set to report on October 28, 2026. Wall Street expects consensus EPS of -$0.67 on revenue of $269.0 million. For trailing context, revenue grew +101.2% year over year last quarter. BridgeBio has beaten EPS in 2 of 8 most recent quarters.

View full earnings history

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a NASDAQ-listed biotechnology company that develops medicines for genetic diseases, cancer-related conditions, and gene therapy applications. In FY2025, it generated $502.1 million of revenue. Founded in 2015 and based in Palo Alto, California, BridgeBio builds its business around a broad clinical pipeline and partnered research base.

Name
BridgeBio Pharma, Inc.
CEO
Neil Kumar
Website
www.bridgebio.com
Industry
Healthcare
Year Founded
2015
Employees
999

Today's Snapshot

AI-generated

BBIO ended the day slightly lower at 65.80, while its sector was weaker.

Trading Volume

Below 10d avg (3.3M)

2.6M

vs S&P 500 Today

Moderate Underperformance

-0.45%

Updated: September 30, 2026 at 20:06 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
BridgeBio displays clear bearish conviction: price is below short-, medium- and long-term moving averages, the ADX indicates a meaningful downtrend, and momentum readings including MACD are negative. RSI is low but not deeply oversold, while ATR shows moderate volatility around the mid-single-digit percentage. OBV is consistent with distribution and the pivot lies above the current price, providing nearby resistance. These elements combine into a coherent downside bias with both momentum and volume favoring sellers. Technical takeaway: Strong Sell — strong trend and selling volume reinforce the bearish signal from moving averages and momentum.
All signals
  • EMA (5 indicators)$67.15 - $74.05
    Sell
  • RSI (14)31.03
    Neutral
  • Stochastic %K (14, 3, 3)15.76
    Buy
  • MACD Level (12, 26)-3.28
    Sell

Peers & Related Assets

MRNAModerna, Inc.
$192.57-5.3%
RVMDRevolution Medicines, Inc.
$205.26+0.4%
ROIVRoivant Sciences Ltd.
$36.57+0.2%
EXELExelixis, Inc.
$58.41-0.4%
JAZZJazz Pharmaceuticals plc
$231.52-0.4%
SMMTSummit Therapeutics Inc.
$16.91+3.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.